AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33079971 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (AVI plus GLUCOSE plus GGT plus SEX plus AGE)
Number of subjects: 2970
Study 33079971 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 3 (BRI plus GLUCOSE plus GGT plus SEX plus AGE)
Number of subjects: 2970
Study 35585558 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture wound closure
Number of subjects: 181
Study 35585558 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture closure
Number of subjects: 181
Study 33644968 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation cephalosporins (group I, 150 patients)
Number of subjects: 300
Study 33644968 — intervention group
Group type: COMPARATOR
Intervention: Second-generation cephalosporins (group II, 150 patients)
Number of subjects: 300
Study 33644968 — intervention group
Group type: COMPARATOR
Intervention: Second-generation cephalosporins (group II)
Number of subjects: 300
Study 33644968 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation cephalosporins (group I)
Number of subjects: 300
Study 32150060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block using a supraglottic device
Number of subjects: 120
Study 32150060 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral nerve block using a supraglottic device
Number of subjects: 120
Study 32150060 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen bronchial intubation
Number of subjects: 120
Study 32150060 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between group I and group P
Number of subjects: 120
Study 36454738 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 0
Study 36454738 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 36454738 — intervention group
Group type: COMPARATOR
Intervention: Talazoparib vs Standard therapy
Number of subjects: 0
Study 33853099 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy for 30 minutes
Number of subjects: 120
Study 33853099 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 120
Study 33565303 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme and actual insulin injection demonstration (physician-led sample insulin injection using an insulin pen)
Number of subjects: 49
Study 33565303 — intervention group
Group type: COMPARATOR
Intervention: Educational programme
Number of subjects: 49
Study 33565303 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 49
Study 34493311 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) prophylaxis
Number of subjects: 54
Study 34493311 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 54
Study 32506857 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinying capsules and oral levofloxacin plus oral metronidazole for first 7 days, followed by Jinying capsules with levofloxacin placebo and metronidazole placebo for another 7 days, and then Jinying capsules only for the remaining 14 days.
Number of subjects: 155
Study 32506857 — intervention group
Group type: COMPARATOR
Intervention: Control group received oral levofloxacin and metronidazole with Jinying capsule placebo for the first 14 days, followed by Jinying capsule placebo only for the remaining 14 days.
Number of subjects: 155
Study 32506857 — intervention group
Group type: COMPARATOR
Intervention: Jinying capsules (experimental group) vs. Jinying capsule placebo (control group) in TCM symptom pattern scores before and after treatment.
Number of subjects: 155
Study 32506857 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicochemical indexes including white blood cell count, erythrocyte sedimentation rate, C-reactive protein, smear of vaginal discharge, and pelvic ultrasound.
Number of subjects: 155
Study 33716034 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 136
Study 33716034 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 136
Study 32318603 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling during three sessions
Number of subjects: 90
Study 32318603 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 90
Study 36299540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with Adaptive Virtual Reality Exposure (CBT-ExpVR)
Number of subjects: 90
Study 36299540 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy with In Vivo Exposure (CBT-Exp)
Number of subjects: 90
Study 33655943 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted left-hand training (n=12)
Number of subjects: 24
Study 33655943 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments for neglect symptoms (n=12)
Number of subjects: 24
Study 33079935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient bar supplementation (2 bars daily for 2 months)
Number of subjects: 36
Study 33079935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutrient bar supplementation)
Number of subjects: 36
Study 36424116 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-education booklet
Number of subjects: 24
Study 34097854 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib-dexamethasone
Number of subjects: 302
Study 34097854 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib-dexamethasone (Control)
Number of subjects: 302
Study 32561260 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week skiing program
Number of subjects: 28
Study 32561260 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 34154896 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training in addition to standard burn rehabilitation (n=14)
Number of subjects: 28
Study 34154896 — intervention group
Group type: COMPARATOR
Intervention: Overground gait training in addition to standard burn rehabilitation (n=14)
Number of subjects: 28
Study 34052212 — intervention group
Group type: EXPERIMENTAL
Intervention: IV continuous diuretic therapy
Number of subjects: 5738
Study 34052212 — intervention group
Group type: COMPARATOR
Intervention: IV intermittent bolus diuretic therapy
Number of subjects: 5738
Study 34052212 — intervention group
Group type: COMPARATOR
Intervention: Oral diuretic therapy
Number of subjects: 5738
Study 36286192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation target of 90% to 94% (intervention; n = 216)
Number of subjects: 428
Study 36286192 — intervention group
Group type: COMPARATOR
Intervention: Oxygen saturation target of 98% to 100% (standard care; n = 212)
Number of subjects: 428
Study 33894156 — intervention group
Group type: EXPERIMENTAL
Intervention: iGBS meningitis
Number of subjects: 2258
Study 33894156 — intervention group
Group type: EXPERIMENTAL
Intervention: Any iGBS disease
Number of subjects: 2258
Study 33894156 — intervention group
Group type: EXPERIMENTAL
Intervention: iGBS disease
Number of subjects: 2258
Study 33894156 — intervention group
Group type: COMPARATOR
Intervention: Household income
Number of subjects: 2258
Study 32513138 — intervention group
Group type: EXPERIMENTAL
Intervention: HA‐WBRT+SIB
Number of subjects: 132
Study 32513138 — intervention group
Group type: COMPARATOR
Intervention: WBRT+SIB
Number of subjects: 132
Study 34518101 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural group (group E) with propofol, fentanyl, rocuronium, and epidural anesthesia with 0.25% levobupivacaine
Number of subjects: 60
Study 34518101 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil group (group R) with remifentanil infusion
Number of subjects: 60
Study 34518101 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 34331840 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mesh
Number of subjects: 0
Study 34331840 — intervention group
Group type: COMPARATOR
Intervention: No mesh
Number of subjects: 0
Study 34331840 — intervention group
Group type: COMPARATOR
Intervention: Biologic mesh
Number of subjects: 0
Study 32320490 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant green tea ingestion with nadolol
Number of subjects: 11
Study 32320490 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea ingestion 1 hour before nadolol
Number of subjects: 11
Study 32320490 — intervention group
Group type: COMPARATOR
Intervention: Water ingestion with nadolol (control)
Number of subjects: 11
Study 35550819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 105
Study 35550819 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Warfarin and antiplatelets)
Number of subjects: 105
Study 35550819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (in patients with MS)
Number of subjects: 105
Study 35550819 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (in patients with MS)
Number of subjects: 105
Study 34257570 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Integrated Boost (SIB) delivered using RapidArc technique at doses of 2.4 Gy per fraction during pelvic irradiation with 50.4/1.8 Gy, total dose of 67.2 Gy for limited volume disease; parametric boost therapy added for advanced disease to a total dose of 79.2 Gy.
Number of subjects: 14
Study 34257570 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous cisplatin‐based chemotherapy for 5 cycles with a dosage of 40 mg/m2.
Number of subjects: 14
Study 36225301 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 20
Study 36225301 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia (NN)
Number of subjects: 20
Study 36225301 — intervention group
Group type: COMPARATOR
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 20
Study 32385765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hydrodilatation via anterior rotator interval approach
Number of subjects: 60
Study 32385765 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided hydrodilatation via posterior intra-articular approach
Number of subjects: 60
Study 34939248 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop and home visit group (n=30)
Number of subjects: 61
Study 34939248 — intervention group
Group type: COMPARATOR
Intervention: Home visit only group (n=31)
Number of subjects: 61
Study 33202482 — intervention group
Group type: COMPARATOR
Intervention: Mechanically assisted walking training without body weight support
Number of subjects: 451
Study 33202482 — intervention group
Group type: COMPARATOR
Intervention: Mechanically assisted walking training with body weight support
Number of subjects: 451
Study 33506796 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary position statements on PFO management in various clinical settings, based on limited and observational or low-certainty randomized data.
Number of subjects: 0
Study 33208155 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive designs
Number of subjects: 0
Study 35084726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heliox (helium/oxygen‐70: 30) plus albuterol (10 mL/min for 20 minutes, three times)
Number of subjects: 109
Study 35084726 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (albuterol in combination with oxygen)
Number of subjects: 109
Study 33370083 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Cycle Deliberate Practice (RCDP) booster training
Number of subjects: 30
Study 33370083 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (plus/delta)
Number of subjects: 30
Study 34091155 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress task
Number of subjects: 30
Study 34091155 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 30
Study 32250418 — intervention group
Group type: EXPERIMENTAL
Intervention: True filtration device
Number of subjects: 43
Study 32250418 — intervention group
Group type: COMPARATOR
Intervention: Sham filtration device
Number of subjects: 43
Study 615776683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed magnetic stimulation (PMS), 2 sessions per week for 2 months (16 sessions)
Number of subjects: 120
Study 615776683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed magnetic stimulation (PMS)
Number of subjects: 120
Study 35450475 — intervention group
Group type: COMPARATOR
Intervention: Endovascular thrombectomy alone
Number of subjects: 1633
Study 35450475 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with intravenous thrombolysis
Number of subjects: 1633
Study 34303029 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+aPDT (scaling and root planing followed by 3 consecutive applications of antimicrobial photodynamic therapy)
Number of subjects: 34
Study 34303029 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 34
Study 35403286 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and Peanut Oral Immunotherapy (PPOIT)
Number of subjects: 62
Study 35403286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 35162622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool water immersion (18 °C)
Number of subjects: 10
Study 35162622 — intervention group
Group type: COMPARATOR
Intervention: Control trial (thermoneutral environment)
Number of subjects: 10
Study 33601335 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Frequency (LF) resistance exercise training (10 × 10 repetitions at 70% one-repetition maximum, once per week)
Number of subjects: 9
Study 33601335 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency (HF) resistance exercise training (2 × 10 repetitions at ∼70% one-repetition maximum, five times per week)
Number of subjects: 9
Study 33601335 — intervention group
Group type: COMPARATOR
Intervention: BASAL (7-day period of habitual physical activity)
Number of subjects: 9
Study 33601335 — intervention group
Group type: EXPERIMENTAL
Intervention: First 2 days of exercise training
Number of subjects: 9
Study 33601335 — intervention group
Group type: EXPERIMENTAL
Intervention: Last 5 days of exercise training
Number of subjects: 9
Study 32546065 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based prehabilitation (EBPrehab) program, two-week duration, including supervised aerobic exercise.
Number of subjects: 230
Study 32546065 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 230
Study 35198631 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation with arthrographic distention
Number of subjects: 180
Study 35198631 — intervention group
Group type: COMPARATOR
Intervention: Arthrographic distention alone (Control)
Number of subjects: 180
Study 32999089 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access with a compression device
Number of subjects: 250
Study 32999089 — intervention group
Group type: COMPARATOR
Intervention: Femoral access with a hemostatic vascular closure device
Number of subjects: 250
Study 32999089 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 250
Study 32999089 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis
Number of subjects: 250
Study 36321798 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary sodium measurement
Number of subjects: 100
Study 36321798 — intervention group
Group type: COMPARATOR
Intervention: Venous sodium measurement
Number of subjects: 100
Study 33392744 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% maximal voluntary contraction (MVC) with wide pulse width (1 ms) NMES
Number of subjects: 20
Study 33392744 — intervention group
Group type: COMPARATOR
Intervention: 30% maximal voluntary contraction (MVC) NMES
Number of subjects: 20
Study 33392744 — intervention group
Group type: COMPARATOR
Intervention: 10% maximal voluntary contraction (MVC) NMES
Number of subjects: 20
Study 33392744 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 2-s NMES bouts
Number of subjects: 20
Study 32967576 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke clock intervention
Number of subjects: 107
Study 32967576 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 35368052 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN360 30 mg
Number of subjects: 32
Study 35368052 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN360 100 mg
Number of subjects: 32
Study 35368052 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN360 300 mg
Number of subjects: 32
Study 35368052 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN360 600 mg
Number of subjects: 32
Study 35368052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 34898916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano‐crystalline silver dressing (Acticoat ™)
Number of subjects: 42
Study 34898916 — intervention group
Group type: COMPARATOR
Intervention: Noneugenol dressing
Number of subjects: 42
Study 32020296 — intervention group
Group type: COMPARATOR
Intervention: Nester coils
Number of subjects: 25
Study 32020296 — intervention group
Group type: EXPERIMENTAL
Intervention: IDC coils
Number of subjects: 25
Study 33758008 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after 3-month DAPT
Number of subjects: 2993
Study 33758008 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 2993
Study 32859432 — intervention group
Group type: EXPERIMENTAL
Intervention: mTNrM staging system
Number of subjects: 18139
Study 32859432 — intervention group
Group type: EXPERIMENTAL
Intervention: mTNrM staging subgroups
Number of subjects: 18139
Study 32859432 — intervention group
Group type: COMPARATOR
Intervention: TNM and TNrM staging systems
Number of subjects: 18139
Study 35717303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregaming Awareness in College Environments (PACE) intervention
Number of subjects: 500
Study 35717303 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 500
Study 36251618 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoketoconazole (150-600 mg BID)
Number of subjects: 60
Study 33148737 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames training (40-minute sessions, 2 times per week for 10 weeks)
Number of subjects: 42
Study 33148737 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy protocol (control group)
Number of subjects: 42
Study 33148737 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames training
Number of subjects: 42
Study 35797395 — intervention group
Group type: EXPERIMENTAL
Intervention: DES with cilostazol
Number of subjects: 85
Study 35797395 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 85
Study 35797395 — intervention group
Group type: COMPARATOR
Intervention: BNS with cilostazol
Number of subjects: 85
Study 35797395 — intervention group
Group type: COMPARATOR
Intervention: BNS
Number of subjects: 85
Study 35797395 — intervention group
Group type: EXPERIMENTAL
Intervention: DES with cilostazol (small vessels)
Number of subjects: 85
Study 35797395 — intervention group
Group type: COMPARATOR
Intervention: DES (small vessels)
Number of subjects: 85
Study 33870762 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 22
Study 33870762 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training plus Kinesio Taping (ET + KT)
Number of subjects: 22
Study 32124456 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin marker intervention using single-use sterile Gentian violet skin marker pens.
Number of subjects: 13991
Study 32124456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no skin marker intervention).
Number of subjects: 13991
Study 32124456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (skin marker and control).
Number of subjects: 13991
Study 32124456 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin marker intervention.
Number of subjects: 13991
Study 33926788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow three-way stopcock (HTS)
Number of subjects: 20
Study 33926788 — intervention group
Group type: COMPARATOR
Intervention: Normal-flow three-way stopcock (NTS)
Number of subjects: 20
Study 34040074 — intervention group
Group type: EXPERIMENTAL
Intervention: V1/V2 ratio
Number of subjects: 100
Study 34040074 — intervention group
Group type: EXPERIMENTAL
Intervention: V2/V3 ratio
Number of subjects: 100
Study 34040074 — intervention group
Group type: EXPERIMENTAL
Intervention: V3/V4 ratio
Number of subjects: 100
Study 34040074 — intervention group
Group type: EXPERIMENTAL
Intervention: V4/V5 ratio
Number of subjects: 100
Study 36643366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked tachosil and restoration of intraabdominal surface tension
Number of subjects: 816
Study 36643366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine-soaked tachosil)
Number of subjects: 816
Study 33609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab Q4W
Number of subjects: 86
Study 33609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab Q8W
Number of subjects: 86
Study 33609624 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Q8W
Number of subjects: 86
Study 33609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Q8W/Q8W
Number of subjects: 86
Study 33609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab Q4W and Q8W
Number of subjects: 86
Study 32788142 — intervention group
Group type: EXPERIMENTAL
Intervention: PediAppRREST app
Number of subjects: 48
Study 32788142 — intervention group
Group type: COMPARATOR
Intervention: Control group (no app)
Number of subjects: 48
Study 32488909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with neoadjuvant chemotherapy (FEC100 and taxanes)
Number of subjects: 132
Study 32488909 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 132
Study 32488909 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 132
Study 36419615 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D dietary supplement containing 150 mg of caffeine
Number of subjects: 17
Study 36419615 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-caffeinated)
Number of subjects: 17
Study 32128957 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide 8 mg once monthly
Number of subjects: 209
Study 32128957 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide 12 mg once monthly
Number of subjects: 209
Study 32128957 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide 16 mg once monthly
Number of subjects: 209